Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

MNI-1216

Radiopharmaceutical · Acts on α-synuclein (SNCA)

Early Phase 1 Most advanced trial (none active)
1 Registered trials

What is MNI-1216?

[18F]MNI-1216 is a radioactive imaging agent administered intravenously for positron emission tomography imaging of α-synuclein deposits in the brain. It is being studied in alpha-synucleinopathies including Parkinson's disease, dementia with Lewy bodies, and multisystem atrophy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Radiopharmaceutical
Targets
α-synuclein (SNCA) (biomarker)
Mechanism
Acts on α-synuclein (SNCA)
Therapy area
Neurology
In trials of
ACIU
FDA status
Investigational, not approved in the US. Most advanced trial: Early Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06445465 Early Phase 1 Alpha-Synucleinopathy Completed ACIU

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alpha-SynucleinopathyDementia With Lewy BodiesMultisystem AtrophyParkinson's Disease

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.